Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Research Grants 17 show all


$15.8M
2013

$788.9K
2014

$1.2M
2016

$17M
2017

$3M
2018

Patents 7,124show all

  • 1,377
    C07K - Peptides
  • 1,197
    A61K - Preparations for medical, dental, or toilet purposes
  • 395
    C12N - Microorganisms or enzymes
  • 330
    A01K - Animal husbandry
  • 285
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 168
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 68
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 60
    C12Y - Enzymes
  • 46
    F02B - Internal-combustion piston engines
  • 43
    G16B - Bioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology

Clinical Trials 657show all

261Phase 3133Phase 295Phase 147N/A45Phase 436Other

SEC Filings show all


227
8-K

71
10-Q

24
10-K

1
D

Contact Information

777 Old Saw Mill River Road
Tarrytown, NY 10591
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$8,900,0005001-100002016-08-22Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2016-08-22$8,900,000Post Ipo EquityU.S. Department of Health & Human Services

SEC Form D Funding Events

DateOfferedSoldType
2003-09-16Unknown Unknown Other (Paper Filing)